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Summary
It is suspected that primary central nervous system lymphoma (PCNSL) rates are increasing 
among immunocompetent people. We estimated PCNSL trends in incidence and survival among 
immunocompetent persons by excluding cases among human immunodeficiency virus (HIV)-
infected persons and transplant recipients. PCNSL data were derived from 10 Surveillance, 
Epidemiology and End Results (SEER) cancer registries (1992–2011). HIV-infected cases had 
reported HIV infection or death due to HIV. Transplant recipient cases were estimated from the 
Transplant Cancer Match Study. We estimated PCNSL trends overall and among 
immunocompetent individuals, and survival by HIV status. A total of 4,158 PCNSLs were 
diagnosed (36% HIV-infected; 0.9% transplant recipients). HIV prevalence in PCNSL cases 
declined from 64.1% (1992–1996) to 12.7% (2007–2011), while the prevalence of transplant 
recipients remained low. General population PCNSL rates were strongly influenced by 
immunosuppressed cases, particularly in 20–39 year-old men. Among immunocompetent people, 
PCNSL rates in men and women aged 65+ years increased significantly (1.7% and 1.6%/year), but 
remained stable in other age groups. Five-year survival was poor, particularly among HIV-infected 
cases (9.0%). Among HIV-uninfected cases, 5-year survival increased from 19.1% (1992–1994) to 
30.1% (2004–2006). In summary, PCNSL rates have increased among immunocompetent elderly 
adults, but not in younger individuals. Survival remains poor for both HIV-infected and HIV-
uninfected PCNSL patients.
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Primary central nervous system lymphoma (PCNSL) is a rare malignancy with an annual 
incidence rate of 7 cases per 1,000,000 people in the U.S. (O’Neill, et al 2013). The rates of 
PCNSL are strongly increased in immunosuppressed populations, particularly among people 
with human immunodeficiency virus (HIV) infection (Gibson, et al 2014). In addition, 
though poorly studied, rates of PCNSL in solid organ transplant recipients are probably 
elevated, as non-Hodgkin lymphoma (NHL) rates are significantly increased (Clarke, et al 
2013). PCNSLs among immunocompetent and immunosuppressed individuals appear to 
have a different aetiology. Most notably, the majority of PCNSLs occurring in HIV-infected 
people and transplant recipients are associated with Epstein-Barr Virus (EBV), whereas 
EBV-related PCNSL cases are uncommon in immunocompetent individuals (Chimienti, et al 
2009).
The HIV epidemic has strongly influenced the occurrence of PCNSL in the U.S. over the 
last several decades. In a prior study, we showed that during 1980–2007, 26.2% of PCNSLs 
in the U.S. occurred among HIV-infected people (Shiels, et al 2011). In the HIV population, 
occurrence of PCNSL has declined over time with effective treatment using highly active 
antiretroviral therapy (HAART) (Engels, et al 2008). In contrast, it has been suggested that 
rates among immunocompetent individuals have increased (Abrey 2009, Chimienti, et al 
2009). Further, one study has shown improvements in survival over time in PCNSL cases 
who were presumed HIV-negative (Norden, et al 2011). However, given the contribution of 
cases occurring in immunosuppressed people to the population-level burden of PCNSL, it is 
not possible to adequately assess trends in immunocompetent PCNSL incidence and survival 
based on overall population data without first removing cases occurring among HIV-infected 
people and solid organ transplant recipients, the largest immunosuppressed populations in 
the U.S.
Prior studies using Surveillance, Epidemiology and End Results (SEER) data for the US 
have indirectly estimated PCNSL incidence and survival in immunocompetent people by 
excluding populations with higher HIV prevalence (i.e., San Francisco area residents, never 
married men and women, and <65 year-olds (O’Neill, et al 2013, Olson, et al 2002), and by 
excluding deaths due to HIV and other infectious diseases (Norden, et al 2011). However, 
these strategies do not fully remove the effect of HIV on PCNSL rates, and also do not 
account for the potential influence of transplant-related PCNSL on general population 
trends. Thus, the aims of this study were to quantify the fraction of PCNSLs that occurred in 
SEER areas among people who are HIV-infected or solid organ transplant recipients, to 
estimate trends in immunocompetent PCNSL after excluding these cases, and to compare 
PCNSL survival by HIV status.
 Methods
 Data sources
Data on PCNSLs were derived from 10 population-based SEER cancer registries in the U.S. 
(i.e., Connecticut, Hawaii, New Mexico, Utah, Atlanta, Detroit, Seattle-Puget Sound, Los 
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Angeles, San Francisco-Oakland, San Jose-Monterey) that had information on HIV status 
for 1992–2011. NHL was defined using SEER site recoding based on the International 
Classification of Diseases for Oncology, 3rd edition (ICD-O-3) and the World Health 
Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008) 
(Fritz, et al 2000, Swerdlow et al 2008). All NHLs with topography codes C70.0–C72.9 
were classified as PCNSLs. Cases with unknown race/ethnicity, unknown age, or gender 
other than male/female were excluded (n=9).
We used SEER data to classify cases by HIV status using two data sources. First, SEER 
registries recorded HIV serostatus at the time of cancer diagnosis (i.e., “HIV flag”) as part of 
the extent of disease field for individuals diagnosed with lymphoma (Clarke and Glaser 
2004, Diamond, et al 2007). 51% of PCNSL cases had missing values for the HIV flag 
(n=2,102). We classified these cases as HIV flag-negative, because the presence of HIV 
infection is generally documented by physicians in medical records, and this flag has been 
shown to be highly sensitive at identifying HIV-infected NHL cases (Clarke and Glaser 
2004, Diamond, et al 2007). Additionally, SEER captures HIV as an underlying cause of 
death from death certificates. Positive HIV status was determined by a positive HIV flag or 
HIV as the underlying cause of death. Of the 2,771 cases that were HIV-negative based on 
the HIV flag alone, 125 (4.5%) were re-classified based on cause of death. As PCNSL is an 
acquired immunodeficiency syndrome (AIDS)-defining condition (Centers for Disease 
Control and Prevention 1992), all PCNSL cases with HIV infection had an AIDS diagnosis.
As SEER registries do not include data on transplantation, we separately estimated the 
number of PCNSLs that occurred among transplant recipients. Data on PCNSLs occurring 
among solid organ transplant recipients during 1992–2011 were ascertained from the 
Transplant Cancer Match (TCM) Study (www.transplantmatch.cancer.gov) (Engels, et al 
2011), a linkage of the U.S. Scientific Registry of Transplant Recipients (SRTR) and 16 
cancer registries. The linkage was approved by the human subjects committees of the 
National Cancer Institute and, as required, participating cancer registries. A total of 147 
PCNSLs linked to the SRTR; none of these cases was also HIV-infected.
 Statistical Analysis
To estimate the number of PCNSLs in SEER that were diagnosed among transplant 
recipients, we multiplied SEER population counts by the incidence of PCNSL in transplant 
recipients, expressed as a fraction of the general population (i.e., defined as number of 
PCNSL cases that linked to the SRTR / general population counts for the cancer registry 
areas). These calculations were carried out in strata defined by calendar year (single years, 
1992–2011), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic and other), 
sex and age (5-year groups from 0–4 to 85+ years).
We calculated the fraction of all PCNSLs that occurred among HIV-infected people and 
transplant recipients by calendar period and demographics. We derived the estimated 
number of immunocompetent PCNSL cases by subtracting HIV-infected and transplant 
recipient PCNSL cases from the total number of PCNSL cases. We then estimated sex- and 
age-stratified time trends in total PCNSL rates and immunocompetent PCNSL rates, age-
standardized to the 2000 U.S. population. Annual per cent changes (APCs) in incidence 
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rates were estimated with Joinpoint regression (Kim, et al 2000, http://
surveillance.cancer.gov/joinpoint/.
We additionally estimated age-standardized survival curves for HIV-infected and HIV-
uninfected PCNSL cases during 1992–2011, using the actuarial method in SEER*Stat, 
version 8.2.1 (http://seer.cancer.gov/seerstat/). To avoid biasing the survival estimates, we 
excluded cases that had been classified as HIV-infected based on cause of death alone. A 
sub-analysis was restricted to cases diagnosed in ≥1998, a time period when HAART was 
widely available. Further, we estimated 5-year survival rates by calendar year of diagnosis 
among HIV-uninfected PCNSL cases during 1992–2006. Cases from 2007–2011 were not 
included due to incomplete 5-year follow-up.
All statistical tests were two-sided with α=0.05.
 Results
During 1992–2011, a total of 4,158 cases of PCNSL occurred during 718 million person-
years in 10 SEER registry areas. Thirty per cent of PCNSLs were not further characterized 
by cell type or histology. Of the remaining 2,906 PCNSLs, 91.6% were B-cell (75.1% 
diffuse large B-cell), 1.5% were T-cell, and 6.9% were NHLs of unknown lineage. PCNSLs 
predominantly occurred in the brain (83.3%), with smaller fractions occurring in the 
meninges, spinal cord and other/unspecified sites. Though 84.2% of cases were 
microscopically-confirmed, this fraction differed substantially by HIV status (93.8% of HIV-
uninfected cases and 67.3% of HIV-infected cases). HIV-infected cases were more likely to 
be diagnosed with only radiographic (26.5% vs. 4.4%) or clinical (4.6% vs. 0.8%) 
confirmation compared to HIV-uninfected cases.
Thirty-six per cent (n=1,512) of cases were HIV-infected and an estimated 0.9% (n=38) 
occurred in solid organ transplant recipients. Immunocompetent PCNSL cases were equally 
common in men and women, while cases occurring in HIV-positive people (91.7%) and 
transplant recipients (57.9%) were more likely to be men (Table I). In immunocompetent 
individuals, the median age at diagnosis was 67 years (estimated by taking the mid-point of 
each 5-year age category), compared to 37 years in HIV-infected people and 52 years in 
transplant recipients. While non-Hispanic white was the most common race/ethnicity in each 
group, larger fractions of cases were minorities in immunosuppressed populations.
Table II presents the proportion of PCNSL cases occurring among HIV-infected people and 
transplant recipients by calendar period, gender, age and race/ethnicity. Over time, the 
fraction of cases occurring in HIV-infected people declined from 64.1% in 1992–1996 to 
12.7% in 2007–2011. The prevalence of HIV was greatest in PCNSL cases who were male 
(50.9% vs. 8.7% in females), particularly men aged 20–39 years (88.5%) and non-Hispanic 
black males (84.6%). Even in the most recent time period (2007–2011), the prevalence of 
HIV was ≥50% among 20–39 year-old and non-Hispanic black men and women with 
PCNSL. The fraction of cases occurring among transplant recipients remained low, but 
increased from 0.4% (1992–1996) to 1.5% (2007–2011).
Shiels et al. Page 4













Figure 1 presents age-standardized incidence rates during 1992–2011 for total and 
immunocompetent PCNSL (i.e., total – immunosuppressed cases) by gender and age group. 
Supplemental Table 1 presents the corresponding APCs for these calendar trends. 
Immunosuppressed cases have had a profound impact on PCNSL rates in men. Total PCNSL 
rates among men declined steeply 30.6%/year (95% confidence interval [CI] -47.9, -7.5) 
during 1995–1998, with non-significant trends prior to and following this time period. 
However, when immunosuppressed cases were excluded, the overall incidence was lower, no 
significant changes in the APC were detected, and there was no longer a significant trend 
over 1992–2011 (APC: 0.72%; 95%CI -0.32–1.77). Similar patterns were observed for 20–
39 and 40–59 year-old men. However, among men aged ≥65 years old, PCNSL rates 
increased over time, both overall (APC: 1.73%; 95%CI 0.29–3.20) and after excluding 
immunosuppressed people (APC: 1.68%; 95%CI 0.33–3.05). Immunosuppressed individuals 
contributed very little to total PCNSL trends among women. No significant trends in APCs 
were observed for total or immunocompetent PCNSL among 20–39 year-old or 40–59 year-
old women during 1992–2011. However, rates significantly increased among 65+ year-old 
women, both overall (APC: 1.86%; 95%CI 0.34–3.40) and without immunosuppressed cases 
(APC: 1.56%; 95%CI 0.06–3.08).
During 1992–2011, survival was poor for PCNSL cases, with just 9.0% (95%CI 3.3–18.3%) 
of HIV-infected cases and 26.2% (95%CI 24.4–28.1%) of HIV-uninfected cases alive five 
years after diagnosis (Figure 2). When restricted to cases diagnosed in 1998–2011, a time 
period when HAART was widely available, 5-year survival only improved slightly to 15.8% 
(95%CI 6.6–28.4%) in HIV-infected cases and 28.9% (95%CI 26.6–31.2%) in HIV-
uninfected cases. We were unable to estimate 5-year survival among HIV-infected 
individuals in more recent time periods because of the small number of people under follow-
up. For HIV-uninfected PCNSL cases, 5-year survival estimates improved from 19.1% 
(95%CI 14.8–23.9) for cases diagnosed during 1992–1994, to 30.1% (95%CI 25.9–34.3) 
during 2004–2006 (Figure 3).
 Discussion
In recent decades, population-based estimates of PCNSL incidence and survival have been 
strongly influenced by cases occurring among HIV-infected individuals. In the presence of 
HIV, it is difficult to discern trends in immunocompetent PCNSL, particularly given the 
dramatic temporal changes in HIV-related PCNSL risk. Though studies have suggested that 
the incidence of PCNSL among immunocompetent people has increased over time, and that 
survival has improved, no prior study has separated out cases occurring among HIV-infected 
people and transplant recipients. For the first time, we show that the rates of PCNSL in the 
immunocompetent U.S. population increased significantly during 1992–2011 among both 
men and women aged 65 years and older, while rates in younger age groups have remained 
unchanged. We also show that though 5-year survival in HIV-uninfected PCNSL cases has 
increased slightly over time, it remains poor.
NHL risk is elevated strongly in HIV-infected people and solid organ transplant recipients 
due to the immunosuppression experienced by these populations (Clarke, et al 2013, Gibson, 
et al 2014). In the setting of immunosuppression, most PCNSLs are caused by the loss of 
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immune surveillance of EBV, resulting in EBV-driven lymphoproliferation (Gloghini, et al 
2013). At the beginning of the AIDS epidemic, PCNSL rates in HIV-infected people were 
elevated 5,000-fold over the general population, but have declined with widespread 
treatment of HIV infection with HAART to a 50-fold increase in the most recent era 
(Engels, et al 2006, Gibson, et al 2014). These strong elevations have contributed 
substantially to population estimates of PCNSL. Indeed, we demonstrate that more than 1 in 
3 cases in US SEER areas during the most recent 20-year period were HIV-infected. These 
estimates far exceed the 6% HIV prevalence estimated among all NHLs during 1992–2009 
(Shiels, et al 2013), and are somewhat higher than our earlier estimate of 26.2% HIV 
prevalence among U.S. PCNSL cases during 1980–2007 (Shiels, et al 2011), probably due to 
the evaluation of different time periods and geographic areas. HIV prevalence was greatest 
among young and non-Hispanic black men, reflecting characteristics of the U.S. HIV-
infected population (Centers for Disease Control and Prevention 2013), and declined over 
time, reflecting a decrease in PCNSL risk with HAART (Engels, et al 2008).
Solid organ transplant recipients take medications that suppress the immune system to 
prevent organ rejection. CNS involvement has been reported to occur in up to 15% of NHL 
cases occurring in this population (Buell, et al 2005), and associated with poor survival 
(Evens, et al 2013). The fraction of PCNSL cases occurring among transplant recipients 
increased slightly during 1992–2011, but remained very low (i.e., 0.9% over the entire time 
period). Transplant-related PCNSL is not well-studied. The increase in the fraction of 
PCNSL cases occurring among transplant recipients is partly due to the overall decline in the 
total number of PCNSL cases in the general population. Furthermore, there has been an 
increase in the number of people living with a transplant (Organ Procurement and 
Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) 
2014). Finally, PCNSL incidence among US transplant recipients has increased, for unclear 
reasons, from 0.003 per 100,000 person-years during 1992–1996 to 0.008 per 100,000 
person-years during 2007–2011 (data not shown).
In order to understand the trends in PCNSL incidence in the immunocompetent population, 
immunosuppressed cases, particularly among younger men, must first be excluded. For the 
first time, we showed that, after the removal of immunocompromised cases, overall rates of 
immunocompetent PCNSL did not increase during 1992–2011. In contrast, rates among men 
and women aged 65+ years have increased 1.7% and 1.6% per year, respectively. By age 
group, trends in PCNSL differed by sex, due to the disproportionate impact of HIV on 
general population rates in men. However, after removing immunocompromised cases, 
trends were similar among males and females. Though prior studies have suggested an 
increase in immunocompetent PCNSL over time, they have relied on surrogates by 
excluding groups of individuals with higher HIV prevalence.(Norden, et al 2011, O’Neill, et 
al 2013, Olson, et al 2002) These approaches are generally inadequate to fully remove HIV-
infected cases. In our data, 33.1% of remaining PCNSL cases were HIV-infected after 
excluding the San Francisco registry, 13.1% after excluding never married men and women, 
and 8.0% after excluding deaths due to HIV and other infectious and parasitic diseases. As 
seen in our study, restricting analyses to cases aged 65+ years adequately selects only 
immunocompetent individuals, as the HIV prevalence in this age group is quite low, but of 
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course this method cannot be used to study trends in PCNSL incidence among younger 
immunocompetent people.
It is unclear why PCNSL rates in older immunocompetent people have increased over time. 
These increasing trends do not reflect patterns observed in the U.S. for other NHL types. 
Though there was a well-documented decades-long increase in NHL rates, we have 
previously shown that rates among HIV-uninfected people in the U.S. have plateaued since 
2004 (Shiels, et al 2013). It has been hypothesized that rates may have risen due to increases 
in detection through heightened surveillance, improved imaging techniques or more frequent 
diagnosis procedures (Abrey 2009). If this were the case, a similar increase in glioma might 
be expected (Olson, et al 2002); however, glioma rates for people aged 65+ years have 
remained stable over this calendar period (Surveillance Epidemiology and End Results 
(SEER) Program 2014). Restricting to microscopically confirmed cases did not notably alter 
CNS lymphoma trends in the oldest age group (men: 1.5% increase per year, p-value=0.07; 
women: 1.7% per year, p-value=0.03), suggesting that secular trends in confirmation have 
not driven the increases in incidence rate. Others have suggested that the increasing use of 
immunosuppressive medications to treat autoimmune conditions in the elderly may be 
contributing to rising PCNSL rates (Villano, et al 2011).
Survival after a PCNSL diagnosis was very poor, particularly among HIV-infected people. 
Poorer survival among HIV-infected patients may reflect severe immunosuppression, more 
aggressive lymphomas, or less frequent treatment (Bayraktar, et al 2011). Some studies have 
shown that HAART improves overall survival of PCNSL patients, and the National 
Comprehensive Cancer Network recommends the consideration of HAART for HIV-infected 
patients (Bayraktar, et al 2011, National Comprehensive Cancer Network 2015). Of note, 
current national guidelines recommend treatment with HAART for all HIV-infected people 
( Panel on Antiretroviral Guidelines for Adults and Adolescents 2015). We observed a 
modest increase in survival among HIV-infected people during 1998–2011, though we were 
unable to restrict the analysis to a more recent period due to a limited number of cases. 
Among immunocompetent individuals, high-dose methotrexate is the recommended first-
line treatment, however there is controversy regarding the optimal induction and 
consolidation regimens, leading to substantial variation in clinical practice (Hoang-Xuan, et 
al 2015, National Comprehensive Cancer Network 2015). Five-year survival in HIV-
uninfected patients improved from 19% to 30% over the ten years from 1992–94 and 2004–
06, probably reflecting improvements in treatment and falling within the range reported by 
recent clinical studies (22–56%) (Ferreri 2011). In spite of this progress, outcomes for 
PCNSL remain poor, and clinical trial enrolment is recommended when feasible (National 
Comprehensive Cancer Network 2015).
A major strength of this study is that it provides the first population-based estimates of 
PCNSL incidence among immunocompetent people (i.e., HIV-uninfected, non-transplant 
recipients). Unlike prior studies that utilized indirect measures to remove HIV-infected 
cases, we were able to directly remove these cases using HIV variables collected by 
registries. In addition, we were able to utilize data from the largest study of cancer in solid 
organ transplant recipients to estimate the number of PCNSLs in transplant recipients. A 
limitation of this study is that the HIV flag collected by the registries was missing in about 
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half of all PCNSLs. Previous studies, albeit in single registry areas, reported that the HIV 
flag has a sensitivity of >90% (Clarke and Glaser 2004, Diamond, et al 2007), so we 
assumed that the flag was probably present when PCNSLs were HIV-infected. Additionally, 
we were unable to remove HIV-infected individuals and transplant recipients from the 
denominator of the immunocompetent incidence rates, because HIV was not a reportable 
condition in all registry areas for the full time period of interest. However, given the low 
prevalence of HIV and transplant recipients in the U.S. general population, incidence rates 
for immunocompetent PCNSL are only slightly underestimated (Shiels, et al 2013). 
Transplant recipients were included in the survival estimates in HIV-uninfected individuals 
but, given the uncommon occurrence of transplant-related PCNSL in this population, this 
should not have affected those estimates. Though we refer to the HIV-uninfected non-
transplant recipient population as “immunocompetent,” we acknowledge that there are other 
immunosuppressed populations that were not excluded, such as bone marrow transplant 
recipients and individuals with congenital immunosuppression, though these individuals are 
unlikely to have had a large impact on the immunocompetent estimates presented here. In 
addition, we could not adjust for treatment in our survival estimates, as the ascertainment of 
chemotherapy treatment is not complete in cancer registries. Finally, our estimates may not 
be representative of the whole US; the SEER Program registries only cover 19% of the U.S. 
population and comprises a mixture of high- and low- HIV prevalence regions.
In conclusion, PCNSLs arising in HIV-infected people have had a profound impact on 
general population rates, particularly among young men. For the first time, we have shown 
that PCNSL rates among young immunocompetent individuals were stable overall during 
1992–2011, but rates increased among the elderly. The cause of increasing rates is unknown, 
and studies on the aetiology and treatment of PCNSL in the elderly are needed. Despite 
improvements in survival over time, prognosis remains poor, and future clinical trials are 
needed in order to continue to make advances in PCNSL survival.
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Age-standardized incidence rates of PCNSL overall and among immunocompetent 
individuals (i.e., excluding HIV-infected people and transplant recipients) in 10 SEER 
registries, 1992–2011. Solid lines indicate overall rates and dashed lines indicate 
immunompetent rates.
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Age-standardized survival estimates for PCNSL cases diagnosed in 10 SEER registries 
during A) 1992–2011 and B) 1998–2011. Solid lines represent HIV-uninfected cases and 
dashed lines represent HIV-infected cases.
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Age-standardized 5-year survival estimates for HIV-uninfected PCNSLs by 3-year 
categories of calendar year of diagnosis in 10 SEER registries during 1992–2005. Points 
represent estimates and dashed lines represent 95% confidence intervals.
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Table I
Characteristics of PCNSL cases occurring among immunocompetent individuals, HIV-infected individuals and 
solid organ transplant recipients in 10 U.S. cancer registries, 1992–2011.
Immunocompetent HIV-infected Transplant recipient
N (%) N (%) N (%)
Total 2608 1512 38
Median age, IQR* 67 (52, 77) 37 (32, 42) 52 (42, 62)
Sex
 Male 1318 (50.5) 1388 (91.7) 22 (57.9)
 Female 1290 (49.5) 124 (8.2) 16 (42.1)
Race/ethnicity
 Non-Hispanic white 1798 (69.0) 778 (51.5) 19 (50.0)
 Other 810 (31.1) 734 (48.5) 19 (50.0)
IQR: interquartile range
*
Median ages were estimated assigning the midpoint value to all cases in each 5-year category.
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